JohnG.QuigleyMD

Oncology • Chicago, IL

Hematologic Oncology

University of Illinois at Chicago

Join to view full profile

Dr. Quigley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Quigley's full profile

Already have an account?

Office
1740 W Taylor St
Chicago, IL 60612
Phone+1 866-600-2273

Fax+1 312-413-7963

Education & Training

University College of Dublin National Univ SOMClass of 1986

Certifications & Licensure

IL State Medical License 2004 - 2026

Clinical Trials

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
COMPLETED
PHASE3
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients Start of enrollment: 2015 Jun 05
Terminated
Phase 1, Phase 2
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Start of enrollment: 2019 Sep 06
Active, not recruiting
Phase 1
Roles: Sponsor-Investigator, Contact, Principal Investigator
Novel Experimental COVID-19 Therapies Affecting Host Response Start of enrollment: 2021 Jul 15
COMPLETED
PHASE2, PHASE3
Roles: Contact
Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Jun 21
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyria.
Cynthia Levy, Hetanshi Naik, Jessica Overbey, Karli Hedstrom, Kelly Wang
Hepatology Communications. 2025-03-01
4 citations
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
Kristine M Erlandson, Linda N Geng, Caitlin A Selvaggi, Tanayott Thaweethai, Peter Chen
Annals of Internal Medicine. 2024-09-01
Richter Syndrome Presenting as Subcutaneous Nodules and a Dermal Plaque.
Melissa Nickles, Samantha Hunt, Saul Turcios-Escobar, Amaara Babwah, Nisreen Mobayed
The American Journal of Dermatopathology. 2024-07-01

Press Mentions

UIC Launches Three COVID-19 Clinical Trials for Blood Clot PreventionNovember 18th, 2020

Grant Support

Flvcr Protein Trafficking And The Regulation Of Heme ExportNational Heart, Lung, And Blood Institute2008–2010

JohnG.QuigleyMD

Dr. Quigley is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.